SkinBioTherapeutics (SBTX) has announced results for its half-year ended 31^st December 2021 which show revenue of just £21,949, cash £1.5 million lower to £3.2 million and include a warning that full-year forecasts will be materially missed – and the shares have responded down to 35p. But here’s why we retain significant confidence and see this as a buying opportunity. From here this could be a 10 bagger.

SkinBioTherapeutics (SBTX) has announced results for its year ended 30^th June 2021 emphasising “transformational” progress. So what is this?

SkinBioTherapeutics (SBTX) has delivered a “Business Update” including that the commercial launch of AxisBiotix-Ps is on track for Q4 and has further encouraging potential, that SkinBiotix manufacturing scale-up with Croda (CRDA) is progressing to schedule and 30^th June year-end cash totalled £4.6 million. Sounds good.

Tom Winnifrith’s ‘Golden Share’ (all proceeds to Woodlarks) from Saturday’s 2017 UK Investor Show has today listed on AIM – and it’s good news…

Optibiotix (OPTI) has announced - not before time we might note- that the demerger of its 52% unit Skinbiotherapeutics and its own AIM listing is underway. I should cocoa. Book building is cracking ahead on the Skinbiotix IPO. Optibiotix currently has an adjusted 52% of Skinbiotherapeutics.

OptiBiotix Health (OPTI) has served up an update which is good but not the sort of fireworks investors were hoping for. As a result the shares closed at 61.5p-63p on the day which is, to say the least, disappointing. They are now 63p-66p which is better but still both disappointing and far too low.

Optibiotix (OPTI) has announced the appointment of Martin Hunt as Chairman and Director of its majority owned subsidiary SkinBiotix Limited. Why does this matter? Because this unit will be spun off with a separate AIM listing well before Christmas. This is one of the last box ticking to do before formal confirmation of the process.